BREATHE-PH study aims to unlock secrets of lung blood pressure in heart failure
NCT ID NCT07537517
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how a specific biological pathway (BMPR2-activin) affects pulmonary hypertension in people with left heart disease. Researchers will follow 150 heart failure patients for one year, using blood tests, imaging, and heart tissue analysis. The goal is to better understand the disease and find new ways to treat it.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could redefine how pulmonary hypertension is classified and point toward new targeted therapies like activin inhibitors.
- What could go wrong
- This is an observational study, not a treatment trial. It will not directly test any therapy, and results may not lead to immediate clinical changes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hospital GU Gregorio Marañón
RECRUITINGMadrid, Madrid, 28007, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital nurse companion: could an app ease the burden of chronic illness?
- Could continuing a common heart drug before surgery save lives?
- Poles apart? nordic walking may outpace standard rehab for heart failure
- Could a gentler tug on the Heart's reins spark recovery?
- Can slow breathing soothe a failing heart?
- Can shedding pounds reboot the Heart's exercise engine?